Nubeqa 300 MG tablet 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FP8LZ
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,508
Award facts
- Contract value 100% obligated
- $11,508.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on January 8, 2026, for Nubeqa 300 mg tablets (120 count) with a ceiling value of $11,508.00. This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by January 30, 2026. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999,999,999.00 vehicle that extends through December 2031 and serves as the primary supply mechanism for pharmaceutical products and medical supplies supporting military healthcare programs globally.
Nubeqa (darolutamide) is a novel androgen receptor inhibitor used in the treatment of advanced prostate cancer, reflecting the Defense Logistics Agency's continued procurement of specialized oncology medications for military healthcare systems. This delivery order exemplifies the routine pharmaceutical supply chain operations under Cencora's comprehensive IDC, which covers an extensive range of brand-name and generic medications, vaccines, medical devices, and other critical healthcare commodities across multiple therapeutic domains. The contract enables the Defense Health Agency and other federal medical institutions to access essential pharmaceutical products efficiently through established procurement vehicles.
Quick answers
Who was awarded contract SPE2DR26FP8LZ?
SPE2DR26FP8LZ was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FP8LZ worth?
The government has obligated $11,508 on SPE2DR26FP8LZ.
Is contract SPE2DR26FP8LZ an order under another contract?
Yes. SPE2DR26FP8LZ is a delivery order under SPE2DR25D3005, an indefinite delivery contract.
Was contract SPE2DR26FP8LZ competed?
The extent of competition for SPE2DR26FP8LZ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award